National Type 2 diabetes working group



## 9 October 2023

Attendees:Pooja Sachdev, Paediatrician, East Midlands – ChairSuma Uday, Paediatrician, West Midlands – Deputy ChairNoina Abid – Paediatrician, Northern Ireland	
Dee Aswani, Paediatrician, Yorkshire & Humber	
Sara Bentwood, Psychologist, London & SEC	
Kate Brennan, Dietitian, Yorkshire & Humber	
Ross Burrows, Paediatric Pharmacist, Wales	
Martha Ford-Adams, Paediatrician, London & SEC	
Ruth Francks, PDSN, East of England	
Evelien Gevers, Paediatrician, London & SEC	
Paul Higgins, Paediatrician, Scotland	
Carolyn Hill, PDSN, South West	
Fainia Kavvoura, Adult Physician, Wessex	
James Law, Paediatrician, East Midlands	
Stacey MacIntyre, PDSN, Wales	
Sarinda Millar, Paediatrician, Northern Ireland	
Ruchi Nadar, Clinical Fellow, West Midlands	
Usha Niranjan, Paediatrician, West Midlands	
Sarah O'Toole, Dietitian, London & SEC	
Leigh Owens, Dietitan, Scotland	
Nisha Pargass, Paediatrician, West Midlands	
Liz Procter, Dietitian, East Midlands	
Radhika Puttha, Paediatrician, West Midlands	
Elise Roberts, Dietitian, London & SEC	
Holly Robinson, NPDA, RCPCH	
Rebecca Ross, Dietitians, East of England	
Lucy Rowe, Network Manager, South West – Notes	
Sandra Rudman, PDSN, South West	
Rajesh Sakremath, Paediatrician, West Midlands	
Rebecca Schoner, Paediatrician, Yorkshire & Humber	
Claire Semple, Psychologist, South West	
Mars Skae, Paediatrician, North West	
Hannah Smith, PDSN, South West	
Anthony Walker, Diabetes UK	
Kamal Weerasinghe, Paediatrician, Wales	
Billy White, Paediatrician, London & SEC	
Natalie White, Dietitian, South West	
Karen Whyte, Paediatrician, Scotland	
Sarah Wocka, Dietitian, Thames Valley	
Heather Clark Network Manager, West Midlands – Notes	
Present: Verity Hawkes, NHSE Diabetes Programme, NHS England (for item 4)	
Apologies: Katie Bareford, Diabetes UK	
Thomas Coles, Dietitian, Wales	
Edel Magee, Dietitian, Northern Ireland	
Carol Metcalfe, PDSN, North West	
Rajeev Raghavan, Adult Physician, West Midlands	
Adele Swart, Dietitian, London & SEC	



# National Type 2 diabetes working group

## 9 October 2023

		Georgina Williams, Paediatrician, Wales
		James Yong, Paediatrician, Yorkshire & Humber
Venue:		MS Teams
1.	Welcon	ne; minutes and matters arising
	chairing achieve	a Sachdev welcomed attendees to the meeting as Chair. Thanks were given to Dr Billy White for g the working group since its establishment and over the last four years. The range of ments and successes in this time were outlined. Billy highlighted the momentum and unities for the group.
	Dr Sum	a Uday was confirmed as Vice Chair.
2.	Update	on ACDC Guidelines
	years ag to CGM study d	eminded the group that the ACDC / BSPED / Network guidelines were published approximately 2 go. Since then, NICE guidelines have been revised, with new medications and increasing access advised. Other topics that need to be covered in the guideline have been highlighted through ay, discussion at this group and the national survey, therefore a review is needed. Members for nd finish group were sought to work alongside representatives from ACDC.
	Dr Eveli	en Gevers offered to assist and was involved in the previous iteration.
	Action 2	${f 1}$ : Heather to circulate a call for Guidelines task and finish group members.
3.	GLP-1 s	hortages and potential use of SGLT2 inhibitors
	•	es are expected to continue into 2024, uncertain when supply will be restored. Advice outlined: Review use and continue only where this has made a difference Do not commence with new patients
		<ul> <li>Liaise with hospital pharmacies as they still have some supply. Encouraged to work with paediatric pharmacists: due to small numbers, limited alternatives, and significance of T2 in CYP, they should be prioritised for GLP-1 medications. Pharmacists may not be aware of the severity for CYP.</li> </ul>
	•	May consider SGLT2 – information is included in the ACDC guidelines; leaflets from adult colleagues can be shared
	•	vas further discussion on use of SGLT2 medications: Dr Fainia Kavvoura was involved in developing the medication section of ACDC guidelines; it has a leaflet for starting their use but this could be updated and made more young people friendly
	•	Could centres trialling medications share their learning? SGLT2 usage may increase as other medications become less available
		Acknowledged there is anxiety about using SGLT2 in paediatrics. Adult service and pharmacist members gave advice and shared experiences <ul> <li>Highlighted DKAs are usually associated with another illness / circumstances i.e. fasting</li> <li>May not be on formulary – main challenge for Wales was prescribing in primary care</li> </ul>



## 9 October 2023

	<ul> <li>Comparative costs outlined</li> </ul>
	• Shared de-escalation criteria and process
	Discussion on infection risk and mitigations including approaches to communicating risks and
	benefits to patients. Noted these are conversations young people with T2 will have with HCPs
	throughout their lives.
	Dr Evelien Gevers presented a case study on use of Empagliflozin.
	There was further discussion on access to CGM for young people with T2 diabetes. NICE states CGM
	should be available if patients are using insulin for T2, if they have additional needs that affect their
	monitoring of glucose levels (as set out in the guidelines) or if testing eight times per day / recurrent or
	severe hypoglycaemia. This will include some but not all patients with T2.
	Members suggested it may be useful to develop this section when the guidelines are reviewed.
4.	Update on NHSE T2 e-learning modules
	Verity Hawkes shared a preview of the T2 in CYP e-learning modules being developed:
	<ul> <li>Will be hosted on e-learning for health</li> </ul>
	Focus on 0-18 years
	• 6 sessions led by expert authors with clinical review by an oversight group consisting of
	members of this group
	• Each module is approximately 30 mins long and contains knowledge checks to be interactive
	<ul> <li>Includes links to NICE, Language Matters and further resources</li> </ul>
	<ul> <li>Finalised sessions then will be promoted at upcoming conferences</li> </ul>
	<ul> <li>Networks will have a role in tracking and encouraging completion</li> </ul>
	<ul> <li>May be able to put monthly updates on Future NHS website.</li> </ul>
	Further discussion included:
	• Members thanked the group and noted that the package was comprehensive and will be useful
	<ul> <li>Is this available to members outside England? Verity to check</li> </ul>
	<ul> <li>It is aimed at any HCP including ward staff and non-specialists.</li> </ul>
	• It is allied at any HCP including ward start and non-specialists.
	Action 2: Verity to update on access for HCPs in other UK regions.
5.	Network updates and work in progress
1	Members shared work and activity underway in Networks:
	• East & West Midlands held their first T2 meeting aiming to provide peer support and explore
	how tertiary centres can support those with smaller numbers. 30 mins operations and 30 mins
	case discussion. To take place 2-monthly.
	<ul> <li>NE &amp; Yorkshire are looking at how to deliver in the regional footprint which spans two</li> </ul>
	Networks. Teams have put forward MDT leads. Aiming to hold monthly drop in case discussion
	sessions to offer support and upskill. Hope to invite adult colleagues in the future. Considering



## 9 October 2023

	what education and training / peer support is provided locally and what is through the national working group. First Year of Care pathway is being trialed
	<ul> <li>working group. First Year of Care pathway is being trialed.</li> <li>East of England have focused on aligning documents for use across the Network. Due to sign off a T2 information booklet. Have produced ACDC summary documents for non-specialist hospital clinicians. Exploring options for structured education based on Desmond / ICAN and delivery format. Working on an activity day for CYP with T2, similar to that provided for CYP with T1.</li> <li>London &amp; SEC have case presentation at the next meeting and are looking at updating the local guidelines</li> <li>Wales are developing a SEREN package for T2 diabetes. Recently held group education with families which was positively received. Will be piloting tertiary clinics at Cardiff soon in conjunction with local teams</li> <li>South West have started a regional MDT meeting across CYA where members can present case studies, invite speakers etc. – this has been well received; due to take place 6-monthly. Developing a champions programme whereby centres are asked to identify one T2 champion and these representatives work on implementation across the region. The first focus will be First Year of Care.</li> </ul>
	<ul> <li>Glasgow have recently established a separate T2 clinic and an audit is underway. A CYP and Adults working group for &lt;40 years across Scotland is being established. There is a national 'difficult diabetes clinical forum' for hospitals to bring cases, both CYP and Adults. This has been very helpful in driving improvement. Exploring how to develop SPIN/GRID for T2 diabetes across Scotland.</li> </ul>
	The importance of collaboration / not duplicating between CYPDNs in England and NHSE was emphasized. Members were encouraged to share resources and examples – please send to Heather.
	The lack of adequate funding for T2 was raised. It was highlighted that Commissioners need to be aware of the serious implications for this age group, and there is a need to bring accountability and reduce variation.
	Action 3: All to send resources / examples to Heather for sharing with the group.
6.	NPDA update
	<ul> <li>Holly Robinson provided an update on the planned Spotlight audit and PREM:</li> <li>T2 analysis from 2021 PREM did not differentiate T1 and T2 within audit. Looking at how best to access T2 data either through HQIP as a patient data request or RCPCH on specific statistics without patient data</li> <li>First Year of Care PREM is underway. If there are sufficient responses and a significant variation in responses for CYP with T2, can undertake a separate analysis</li> <li>T2 Spotlight is planned for early 2024. Needs to be a similar dataset to last time to enable comparison and review progress. Dataset and Methodology group have been asked about potential updates, e.g. to reflect medication changes and CEW</li> <li>NHSE approached NPDA on inclusion of learning disabilities within T2 Spotlight. Consideration factors and potential meaningful data to be extracted were summarised. Members were asked for their experiences. Anecdotally in CEW, high levels of neurodiversity and reflected in T2 cohort to some extent but there is a range of needs and not clear whether diagnoses are</li> </ul>
	formal or not. Noted national challenges and criteria around neurodiversity diagnosis and



# National Type 2 diabetes working group

## 9 October 2023

	support. Epidemiological data would be useful, but need better parameters to identify. Not possible with current IT systems and manual data submission.
	Action 4: Holly to share plans for T2 Spotlight.
7.	Working group priorities for 2024
	<ul> <li>The group discussed priority areas for 2024. The following Task and Finish groups were agreed:</li> <li>Annual Study day (potentially more frequent). Proposed this takes place in March</li> <li>Guidelines group</li> <li>First Year of Care – to bring together what people are working on</li> <li>Resources for Libre at diagnosis – bespoke resources needed as education and support will be different</li> <li>Medication information for CYP and parents</li> <li>Ongoing work with DigiBete for T2 platform</li> <li>Volunteers for each group were sought noting the importance of MDT representation. It was proposed that groups have designated leads who join monthly check-ins to share updates and feedback into the national working group.</li> <li>Dr Dee Aswani emphasized that there is lots of good practice happening; it would be beneficial to combine efforts nationally. All Networks and regions were encouraged to be represented and involved.</li> <li>Holly reminded members that NPDA has a small budget for engagement and QI related to audit findings. The group were encouraged to contact Holly with ideas.</li> <li>Action 5: All to contact Heather if interested in joining the task and finish groups.</li> </ul>
	Action 5. An to contact neather in interested in joining the task and initial groups.
8.	<ul> <li>Research update</li> <li>Dr Suma Uday updated the group: <ul> <li>LEGEND – due to start recruitment next year</li> <li>Pioneer Teens – have been difficulties recruiting. The inclusion criteria have been revised and there is increased eligibility</li> <li>PICS sites have been opened to increase contribution</li> <li>SURPASS – ongoing in Leicester.</li> </ul> </li> </ul>
9.	Next meeting Invite to be circulated for end of January; meetings will take place three times a year.